Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “AKT1”

18 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 18 of 18 results

Early research (Phase 1)Study completedNCT02594215
What this trial is testing

Dose Finding Trial of MK-7075 in Children and Adults With Proteus Syndrome

Who this might be right for
Proteus Syndrome
National Human Genome Research Institute (NHGRI) 6
Testing effectiveness (Phase 2)Active Not RecruitingNCT05498896
What this trial is testing

Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC

Who this might be right for
Triple Negative Breast Cancer
Queen Mary University of London 146
Early research (Phase 1)Ended earlyNCT02476955
What this trial is testing

Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

Who this might be right for
Solid TumorsOvarian CancerEndometrial Cancer
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 41
Testing effectiveness (Phase 2)UnknownNCT02340845
What this trial is testing

Bromelain, Comosain as a New Drug for Treating and Preventing Various Types of Cancer in the Humans

Who this might be right for
Cancer
Oeyama-Moto Cancer Research Foundation 100
Testing effectiveness (Phase 2)Study completedNCT01028495
What this trial is testing

A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer

Who this might be right for
Metastatic Pancreatic Cancer
Rexahn Pharmaceuticals, Inc. 31
Early research (Phase 1)Study completedNCT03310541
What this trial is testing

AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations

Who this might be right for
Breast CancerProstate CancerAdvanced Solid Tumors
Memorial Sloan Kettering Cancer Center 12
Early research (Phase 1)UnknownNCT05267899
What this trial is testing

A Phase I First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WGI-0301 in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Zhejiang Haichang Biotech Co., Ltd. 24
Early research (Phase 1)Study completedNCT01473095
What this trial is testing

Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma

Who this might be right for
Solid TumorMalignant LymphomaTumor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 120
Early research (Phase 1)Active Not RecruitingNCT07038369
What this trial is testing

ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

Who this might be right for
Advanced Solid TumorsBreast CancerBreast Carcinoma+24 more
Atavistik Bio, Inc 134
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07486648
What this trial is testing

Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib

Who this might be right for
Lung Cancer (NSCLC)Lung Cancer (Non-Small Cell)Advanced Non-small-cell Lung Cancer
Shanxi Province Cancer Hospital 53
Early research (Phase 1)Ended earlyNCT02761694
What this trial is testing

Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001)

Who this might be right for
CancerSolid Tumors
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 78
Early research (Phase 1)Study completedNCT01915576
What this trial is testing

Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients

Who this might be right for
Neoplasms
Bayer 79
Testing effectiveness (Phase 2)Looking for participantsNCT04316546
What this trial is testing

MK-7075 (Miransertib) in Proteus Syndrome

Who this might be right for
Proteus Syndrome
National Human Genome Research Institute (NHGRI) 45
Early research (Phase 1)Looking for participantsNCT06533059
What this trial is testing

Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

Who this might be right for
CancerBreast CancerEndometrial Cancer+2 more
Alterome Therapeutics, Inc. 110
Not applicableUnknownNCT01075373
What this trial is testing

A Neurobiological Study on Heterogeneity of Schizophrenia: Genetic Variations and Neurobiological Differentiations

Who this might be right for
Schizophrenia
National Taiwan University Hospital 360
Large-scale testing (Phase 3)Study completedNCT03337724
What this trial is testing

Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 579
Early research (Phase 1)Study completedNCT01226316
What this trial is testing

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Who this might be right for
Advanced Solid MalignancySafety and TolerabilityPharmacokinetics+11 more
AstraZeneca 285
Large-scale testing (Phase 3)Active Not RecruitingNCT06764186
What this trial is testing

A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain

Who this might be right for
Locally Advanced or Metastatic Breast Cancer
AstraZeneca 101